Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Opsens Inc T.OPS

Healthcare Medical Devices
OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

Recent & Breaking News (TSX:OPS)

OpSens (TSX:OPS) awarded diagnostics agreement

Caroline Egan  July 11, 2022

OpSens Awarded Interventional Specialty Diagnostics Agreement with Premier for OptoWire III

Canada NewsWire July 11, 2022

OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JULY 14

Canada NewsWire July 7, 2022

OPSENS ANNOUNCES GLOBAL SAVVYWIRE(TM) FIRST COMMERCIAL USE

Canada NewsWire June 7, 2022

OPSENS SAVVYWIRE(TM) FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULTANEOUSLY PUBLISHED IN EUROINTERVENTION JOURNAL

Canada NewsWire May 19, 2022

OPSENS ANNOUNCES PUBLICATION IN JSCAI OF DATA SUPPORTING THE CORRELATION BETWEEN THE OPTOWIRE AND A NOVEL TAVR INTERFACE WITH STANDARD OF CARE, BEFORE AND AFTER TAVR

Canada NewsWire May 18, 2022

OPSENS ANNOUNCES HEALTH CANADA APPROVAL FOR ITS NEW TAVR GUIDEWIRE

Canada NewsWire April 26, 2022

OPSENS ANNOUNCES SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS

Canada NewsWire April 13, 2022

OPSENS TO HOST SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON WEDNESDAY, APRIL 13

Canada NewsWire April 6, 2022

OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th to 17th

Canada NewsWire March 14, 2022

OpSens Reports on Voting Results from its Annual Shareholders Meeting

Canada NewsWire February 25, 2022

OPSENS APPOINTS BRAD DAVIS AS NEW CHIEF COMMERCIAL OFFICER

PR Newswire February 9, 2022

OPSENS ANNOUNCES ABIOMED 4-YEAR SUPPLY AGREEMENT EXTENSION TO 2028

PR Newswire February 1, 2022

OPSENS NAMED TO 2022 OTCQX BEST 50

PR Newswire January 24, 2022

OpSens Announces FIRST Quarter fiscal 2022 Financial Results

PR Newswire January 13, 2022

OPSENS TO HOST FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, JANUARY 13, 2022

PR Newswire January 6, 2022

OPSENS ANNOUNCES 510(K) SUBMISSION TO U.S. FDA FOR NEW GUIDEWIRE FOR THE TAVR PROCEDURE

PR Newswire December 13, 2021

Opsens to Present at the Lytham Partners Winter 2021 Investor Conference: Presentation at 11 Am (ET), Monday December 13, 2021

PR Newswire December 7, 2021

OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results

PR Newswire November 23, 2021

OpSens Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

PR Newswire November 23, 2021